StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL – Free Report) in a research report report published on Friday. The brokerage issued a sell rating on the medical technology company’s stock.
Other research analysts also recently issued research reports about the company. Benchmark reiterated a speculative buy rating and set a $0.40 price target on shares of BIOLASE in a report on Wednesday, October 2nd. Ascendiant Capital Markets reduced their target price on shares of BIOLASE from $3.50 to $2.00 and set a buy rating for the company in a research note on Tuesday, September 3rd.
View Our Latest Analysis on BIOLASE
BIOLASE Trading Down 72.0 %
BIOLASE (NASDAQ:BIOL – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The medical technology company reported ($0.08) EPS for the quarter. BIOLASE had a negative net margin of 41.65% and a negative return on equity of 1,782.73%. The firm had revenue of $11.56 million during the quarter.
Hedge Funds Weigh In On BIOLASE
A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC boosted its position in BIOLASE, Inc. (NASDAQ:BIOL – Free Report) by 1,068.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 143,537 shares of the medical technology company’s stock after buying an additional 131,248 shares during the quarter. Virtu Financial LLC owned approximately 0.43% of BIOLASE worth $27,000 at the end of the most recent reporting period. 8.79% of the stock is currently owned by hedge funds and other institutional investors.
About BIOLASE
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.
Read More
- Five stocks we like better than BIOLASE
- EV Stocks and How to Profit from Them
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- Where to Find Earnings Call Transcripts
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- What Do S&P 500 Stocks Tell Investors About the Market?
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.